title: Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected.
abstract: Administration of an angiotensin II receptor antagonist (ARB) during the second trimester of pregnancy is known to cause irreversible renal damage in the fetus. We report a case in which ARB was given to the mother from the first trimester until 26 weeks' gestation. The patient had diabetic nephropathy with accompanying nephrotic syndrome. At 8 weeks' gestation, she was started on candesartan cilexetil (an ARB). At 26 weeks' gestation, she was transferred to our center. Severe oligohydramnios was noted. The pregnancy was terminated, and she delivered at 27 weeks' gestation. The neonate weighed 884 g and died 1 h after birth. Autopsy revealed that the lung/bodyweight ratio was 0.0096 (>0.015) and pulmonary hypoplasia was noted. Histological examination of the kidneys showed tubular dysgenesis with poor differentiation of the proximal tubules.
authors.affiliation: Maternity and Neonate Center, Yokohama City University Medical Center, Urafune-cho, Minami-ku, Yokohama, Kanagawa, Japan. p_kaorunrun@yahoo.co.jp
authors.forename: Kaoru
authors.initials: K
authors.lastname: Kato
authors.forename: Mika
authors.initials: M
authors.lastname: Okuda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ishikawa
authors.forename: Tsuneo
authors.initials: T
authors.lastname: Takahashi
authors.forename: Fumiki
authors.initials: F
authors.lastname: Hirahara
mesh_terms: D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000473:pathology; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007231:Infant, Newborn; D008168:Lung / Q000473:pathology*; D016104:Oligohydramnios / Q000139:chemically induced* / Q000473:pathology; D011247:Pregnancy; D011254:Pregnancy in Diabetics / Q000473:pathology; D013777:Tetrazoles / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; C077793:candesartan cilexetil